Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing

Area of Science:

• Biomedical Engineering
• Drug Delivery
• Cancer Research

Background:

• Conventional experimental models for drug delivery face limitations in physiological relevance and translational predictability.
• Microfluidic tumor-on-chip platforms offer a controlled environment to study the tumor microenvironment (TME).
• Incorporating extracellular matrix (ECM) mimics enhances the fidelity of these in vitro models.

Purpose of the Study:

• To review the application of microfluidic matrix-integrated tumor-on-chip platforms for drug delivery evaluation.
• To discuss the engineering of TME features within microfluidic models.
• To examine the assessment of various therapeutic strategies using these advanced platforms.

Main Methods:

• Focus on microfluidic platforms engineered with ECM mimics to replicate solid tumor characteristics.
• Analysis of how transport dynamics and delivery mechanisms are modeled under physiologically relevant conditions.
• Review of therapeutic strategies evaluated, including nanocarriers, biologics, and cell-based therapies.

Main Results:

• Matrix-integrated tumor-on-chip platforms provide enhanced physiological relevance for drug delivery studies.
• These models allow for the investigation of drug penetration, transport dynamics, and therapeutic responses.
• Demonstrated utility in assessing diverse therapeutic modalities and improving preclinical predictions.

Conclusions:

• Microfluidic matrix-integrated tumor-on-chip technologies are powerful preclinical tools for drug delivery evaluation.
• These platforms bridge the gap between in vitro assays and in vivo studies.
• They accelerate the translation of drug delivery systems and support personalized medicine.